Keyword: Wistar Institute
A personalized ovarian cancer vaccine was most effective when given alongside a pair of approved cancer meds.
A Stanford team aimed at host cells to fight flaviviruses, while Harvard scientists examined the longevity of Zika vaccines.
A synthetic DNA vaccine developed by the Wistar Institute and Penn scientists, with support from Inovio and GeneOne, shows promise in human trials.
OncoCyte, which is developing blood-based tests to catch cancer early, announced Monday that its lung cancer diagnostic succeeded in a 300-patient study.
For the first time, researchers have tested a Zika vaccine in animals that do not have a natural resistance to the virus. The synthetic DNA jab protected 100% of vaccinated animals from Zika infection, brain damage and death.
Wistar Institute scientists have found that cell senescence can also cause side effects that benefit tumors. Manipulating the levels of a certain protein may lead to methods to promote the benefits of senescence while tamping down on its negative effects.
Researchers at the Wistar Institute in Philadelphia have found a new class of drugs that can reduce a tumor’s resistance to chemotherapy.
Wistar Institute scientists have found that, in addition to driving breast and ovarian cancer growth, the hormone estrogen plays a role in tamping down the immune response against various cancers.
Wistar Institute scientists have found a class of drugs that effectively dampened PD-L1 activity in ovarian cancer, even though it does not directly target PD-L1. Called bromodomain and extraterminal domain (BET) inhibitors, multiple candidates are in clinical trials for other cancers.
Wistar Institute scientists have used a modified version of CAR-T to target ovarian tumors in a new approach that could reduce the likelihood of recurrent cancer.